Verve Therapeutics, Inc. Class Action Lawsuit - VERV
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Verve Therapeutics class action lawsuit seeks to represent purchasers or acquirers of Verve Therapeutics, Inc. (NASDAQ: VERV) publicly traded securities between August 9, 2022 and April 1, 2024, inclusive (the “Class Period”). Captioned Oldroyd v. Verve Therapeutics, Inc., No. 24-cv-12218 (D. Mass.), the Verve Therapeutics class action lawsuit charges Verve Therapeutics and certain of Verve Therapeutics’ top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Verve Therapeutics class action lawsuit, please provide your information in the form on this page. You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Verve Therapeutics class action lawsuit must be filed with the court no later than October 28, 2024.
CASE ALLEGATIONS: Verve Therapeutics is a clinical-stage genetic medicines company that engages in developing gene editing medicines for patients to treat cardiovascular diseases. According to the Verve Therapeutics class action lawsuit, during the Class Period, Verve Therapeutics was engaged in the Heart-1 Phase 1b clinical trial of VERVE-101, “a novel, investigational gene editing medicine . . . designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol.”
The Verve Therapeutics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants did not fully disclose the circumstances under which the Heart-1 trial would be halted; and (ii) defendants overstated the potential benefits of its proprietary lipid nanoparticles (“LNP”) delivery system.
The Verve Therapeutics class action lawsuit further alleges that on April 2, 2024, Verve Therapeutics disclosed that the Heart-1 clinical trial would be halted due to an adverse event in an individual who had been dosed at 0.45 mg/kg of VERVE-101, and that the LNP delivery system was to blame. On this news, the price of Verve Therapeutics stock fell nearly 35%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Verve Therapeutics publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Verve Therapeutics class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Verve Therapeutics class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Verve Therapeutics class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Verve Therapeutics class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig.